Ultivue

Ultivue is a company specializing in multiplexing tools and image analysis solutions for tissue biomarker studies. The company's proprietary InSituPlex technology enables advanced exploration and interrogation of tissue samples for precision medicine research. This technology allows for fast and comprehensive exploration of up to 12 biologically relevant targets in one tissue slide, with same-slide hematoxylin and eosin (H&E) analysis. Ultivue's platform combines computational pathology and spatial biology to guide translational science in immuno-oncology.

The company offers VUE biomarker panels, which provide translational and clinical researchers with pre-optimized yet configurable, as well as custom biomarker assays. These panels yield more precise insights than less quantitative methods, delivering results 70% faster while leveraging existing lab infrastructure. Ultivue's solutions are designed for use in both multiplex immunofluorescence (mIF) imaging and spatial phenomics.

Ultivue's Spatial Image Analysis pipeline utilizes AI and advanced analytics approaches to unlock quantitative insights into the spatial biology of tumor microenvironments. The company's cross-functional team of pathology, translational biology, and data science experts uses advanced Deep Learning and a proprietary image analysis pipeline to deliver comprehensive cell phenotyping and cohort-level results.

In March 2022, Ultivue expanded its capabilities by partnering with Aignostics to offer AI-powered image analysis services. This collaboration aims to provide more consistent and reproducible readouts at scale for both translational research and clinical trial services in Ultivue's CLIA accredited clinical research laboratory.

Key customers and partnerships

Ultivue has established several key partnerships to enhance its offerings and reach in the biomedical research field. In October 2022, the company entered into an agreement with Carl Zeiss Microscopy, LLC to co-market Ultivue's multiplex biomarker assays for tissue phenotyping with the ZEISS Axioscan whole slide imaging system. This partnership aims to provide a streamlined solution for multiplex tissue analysis in applications such as cancer biology, immunology, and drug development.

In April 2022, Ultivue announced a collaboration with Paige, a leader in AI-based diagnostic software in pathology. This partnership focuses on developing AI to improve understanding of the tumor microenvironment and support the interpretation of Ultivue's novel multiplex immunofluorescence immuno-oncology biomarker panels.

Ultivue has also formed partnerships with other companies in the AI and image analysis space, including Visiopharm, Indica Labs, OracleBio, Keen Eye, and Nucleai. These collaborations aim to offer end-to-end support for customers and provide flexible image analysis solutions for biomarker discovery and validation.

The company serves a diverse range of customers, including researchers in academia, biotech, pharmaceuticals, and contract research organizations. Ultivue's technologies and services are particularly relevant for those working in translational medicine, immuno-oncology, and precision medicine research.